Jim Cramer expressed uncertainty about the future of Eli Lilly (NYSE: LLY) despite backing the company. He mentioned the potential short-term peak in the use of GLP-1 drugs and the need for breakthroughs in new areas for the company to break out.

Eli Lilly (NYSE: LLY) is involved in research, development, and sales of pharmaceutical products focusing on diabetes, cancer, autoimmune disorders, pain, and migraines. The company is exploring various therapies in these areas to enhance its portfolio.

While Eli Lilly (NYSE: LLY) shows investment potential, some believe that certain AI stocks offer better upside potential with less downside risk. Investors looking for undervalued AI stocks benefiting from current trends may find better options elsewhere.

For more insights on potential stock investments, consider exploring reports on stocks that are expected to double in three years or hidden AI stocks with growth potential. This information can help investors diversify their portfolios and capitalize on emerging trends in the market.

Read more at Yahoo Finance: “It Needs Breakthroughs in New Areas”